Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (RADIO-LYMPH)
|ClinicalTrials.gov Identifier: NCT02867553|
Recruitment Status : Unknown
Verified September 2016 by CHU de Reims.
Recruitment status was: Active, not recruiting
First Posted : August 16, 2016
Last Update Posted : September 7, 2016
Cutaneous lymphomas are the most frequent extranodal lymphomas after digestive lymphomas. A quarter are B-cell lymphomas. 80% of cutaneous B cell lymphomas are indolent cutaneous B cell lymphomas. These indolent cutaneous B cell lymphomas are characterized by good prognosis (survival rate at 5 years: 90%), but also by the frequency of cutaneous recurrences. The radiotherapy is currently the most widely used treatment, with complete response rate close to 100% for a lesion treated. However, it has limits when there are outset multiple lesions inaccessible to a single radiotherapy field (concerning one case in three), or during recurrences. In these situations, conventional chemotherapy is not recommended and multi-field radiotherapy is often used empirically, but its effectiveness has never been studied prospectively.
Recently, retrospective studies with small numbers patients (totaling sixty patients) reported complete response rates of 80 to 100% with rituximab (anti-cluster of differentiation antigen 20 (CD20) antibodies) used as monotherapy in non-standardized treatment by intravenous with a recurrence rate of less than one case in three. These data suggest that rituximab by intravenous with a standardized initial cycle followed by a maintenance therapy could improve the prognosis of indolent cutaneous B cell lymphomas with multiple lesions or of recurrent lesions.
|Condition or disease||Intervention/treatment||Phase|
|Indolent Cutaneous B Cell Lymphomas||Drug: rituximab Radiation: Multi-fields radiotherapy||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||January 2019|
Experimental: Rituximab by intravenous
attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
Active Comparator: multi-field radiotherapy
multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
Radiation: Multi-fields radiotherapy
- Disease free survival [ Time Frame: 5 years ]Disease free survival
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02867553
|Chu de Reims|
|Reims, France, 51092|